

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

GLS2 Antibody (C-term E513)

RRID:AB_10818414

Type: Antibody

Proper Citation

abcepta Cat# AP6650d, RRID:AB_10818414

Antibody Information

URL: http://antibodyregistry.org/AB_10818414

Proper Citation: abcepta Cat# AP6650d, RRID:AB_10818414

Target Antigen: GLS2 (C-term E513)

Host Organism: rabbit

Clonality: monoclonal

Comments: manufacturer recommendations: ELISA; Immunohistochemistry; Western Blot; WB,IHC,E

Antibody Name: GLS2 Antibody (C-term E513)

Description: This monoclonal targets GLS2 (C-term E513)

Target Organism: h, m, mouse, human

Antibody ID: AB_10818414

Vendor: abcepta

Catalog Number: AP6650d

Record Creation Time: 20250820T053934+0000

Record Last Update: 20250820T220803+0000

Ratings and Alerts

No rating or validation information has been found for GLS2 Antibody (C-term E513).

No alerts have been found for GLS2 Antibody (C-term E513).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tong M, et al. (2021) Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. Cell reports, 36(8), 109617.

Lukey MJ, et al. (2019) Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. Cell reports, 29(1), 76.